You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 13, 2024

Investigational Drug Information for Gepotidacin


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Gepotidacin?

Gepotidacin is an investigational drug.

There have been 12 clinical trials for Gepotidacin. The most recent clinical trial was a Phase 2 trial, which was initiated on October 17th 2019.

The most common disease conditions in clinical trials are Bacterial Infections, Communicable Diseases, and Infections. The leading clinical trial sponsors are GlaxoSmithKline, Biomedical Advanced Research and Development Authority, and Barda (Contract No HHSO100201300011C).

There are three US patents protecting this investigational drug and one hundred and nine international patents.

Recent Clinical Trials for Gepotidacin
TitleSponsorPhase
A Study to Investigate the Efficacy and Safety With Gepotidacin in Japanese Female Participants With Uncomplicated Urinary Tract Infection (Acute Cystitis)GlaxoSmithKlinePhase 3
A Study to Evaluate Pharmacokinetic, Safety, Tolerability and Relative Bioavailability of Gepotidacin in Healthy Adult Male and Female ParticipantsGlaxoSmithKlinePhase 1
Penetration of the Innovative Antibiotic Gepotidacin Into Prostate and Tonsillar TissueMedizinischen Universit├Ąt WienPhase 1

See all Gepotidacin clinical trials

Clinical Trial Summary for Gepotidacin

Top disease conditions for Gepotidacin
Top clinical trial sponsors for Gepotidacin

See all Gepotidacin clinical trials

US Patents for Gepotidacin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Gepotidacin ⤷  Sign Up Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Sign Up
Gepotidacin ⤷  Sign Up Mutagenizing intracellular nucleic acids BIOLOGICAL RESEARCH CENTRE (Szeged, HU) ⤷  Sign Up
Gepotidacin ⤷  Sign Up Anti-wall teichoic antibodies and conjugates Genentench, Inc. (South San Francisco, CA) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Gepotidacin

Drugname Country Document Number Estimated Expiration Related US Patent
Gepotidacin Australia AU2017261372 2036-05-05 ⤷  Sign Up
Gepotidacin Canada CA3023278 2036-05-05 ⤷  Sign Up
Gepotidacin China CN107847398 2036-05-05 ⤷  Sign Up
Gepotidacin European Patent Office EP3452003 2036-05-05 ⤷  Sign Up
Gepotidacin European Patent Office EP3981392 2036-05-05 ⤷  Sign Up
Gepotidacin Hong Kong HK1249728 2036-05-05 ⤷  Sign Up
Gepotidacin Japan JP2019520866 2036-05-05 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.